Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

PSA decrease during combined-modality radiotherapy predicts for treatment outcome.

Gregory J Kubicek1, Marco Naguib, Sandy Redfield

  • 1Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.

International Journal of Radiation Oncology, Biology, Physics
|February 23, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-fraction monitoring of brain metastases resection cavities during fractionated stereotactic radiosurgery on the 0.35 T MRI-Linac.

Journal of radiosurgery and SBRT·2026
Same author

Magnetic Resonance Imaging Relaxometry for Glioblastoma Response Assessment During Radiation Therapy on a 0.35 T Magnetic Resonance Imaging Linear Accelerator.

International journal of radiation oncology, biology, physics·2025
Same author

Transportation considerations in underserved patient populations receiving multidisciplinary head and neck cancer care.

AIMS public health·2025
Same author

The Effect of <i>Saccharomyces cerevisiae</i> Fermentation Product Supplementation on Pro-Inflammatory Cytokines in Holstein Friesian Cattle Experimentally Inoculated with Digital Dermatitis.

Animals : an open access journal from MDPI·2024
Same author

Prompt Engineering Paradigms for Medical Applications: Scoping Review.

Journal of medical Internet research·2024
Same author

Validation of daily 0.35 T diffusion-weighted MRI for MRI-guided glioblastoma radiotherapy.

Medical physics·2024

A mid-treatment prostate-specific antigen (PSA) decrease after external beam radiation therapy (EBRT) predicts better survival in prostate cancer patients receiving brachytherapy. This finding aids in risk stratification and potential treatment intensification.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Prostate-specific antigen (PSA) is crucial for prostate cancer management.
  • Pretreatment PSA, doubling time, and nadir levels are established prognostic markers.
  • The prognostic value of PSA during radiotherapy is less understood.

Purpose of the Study:

  • To evaluate the significance of mid-radiotherapy PSA levels in predicting outcomes for prostate cancer patients.
  • To assess if a decrease in PSA during external beam radiation therapy (EBRT) correlates with improved survival.
  • To determine the utility of mid-treatment PSA as a risk stratification tool.

Main Methods:

  • Retrospective analysis of 717 prostate cancer patients undergoing EBRT followed by low-dose-rate brachytherapy (LDR).

Related Experiment Videos

Last Updated: Jun 16, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

  • Mid-treatment PSA (midPSA) levels were measured after EBRT and before LDR.
  • Patient outcomes, including overall survival and disease-free survival, were analyzed in relation to midPSA changes.

    • Main Results:

    • A decrease in midPSA after EBRT was observed in 653 patients (median decrease of 6.2 ng/mL).
    • Patients with a midPSA decrease ≥25% showed significantly improved overall survival (10.0 vs. 7.4 years) and disease-free survival (9.8 vs. 7.3 years).
    • The predictive value of midPSA decrease remained significant regardless of androgen blockade use.

    Conclusions:

    • Mid-treatment PSA response following EBRT is a significant predictor of long-term outcomes in prostate cancer patients.
    • This finding supports using midPSA for risk stratification before brachytherapy.
    • Potential for dose escalation with higher LDR doses in patients with favorable midPSA response to further improve outcomes.